Roche's Itovebi Approved for Breast Cancer, Poses Challenge to Novartis

Roche has introduced Itovebi, a newly approved drug set to enhance its breast cancer treatment portfolio. Approved by the FDA, Itovebi is designed for first-line treatment of HR-positive, HER2-negative breast cancer with PIK3CA mutations and is used in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex[1][2]. Itovebi demonstrated a 57% reduction in disease progression risk and showed improved safety with a lower incidence of high-grade hyperglycemia compared to Novartis' Piqray[2]. With this development, Roche anticipates significant market impact, projecting peak sales of up to $2.3 billion, posing a competitive challenge to existing players in the field[1].